CRA experts advised two parties during both the CMA’s investigation and CAT Appeals, assessing the economic evidence and providing expert testimony on what prices could be considered excessive (or, to the contrary, consistent with competitive outcomes) in the UK market for Liothyronine tablets.
The Role of Uncertainty in the Future European Horizontal Merger Guidelines: Lessons Learned From Illumina/GRAIL
Under these circumstances, it is however not entirely clear how the future competitive landscape will look like, merger effects cannot be modelled with a high...